NEUROCRINE BIOSCIENCES, INC. (NASDAQ:NBIX) Files An 8-K Other Events
Item8.01 Other Events.
On April11, 2017, Neurocrine Biosciences, Inc. announced that the
Food and Drug Administration (FDA) has approved
INGREZZATM (valbenazine)
capsules for the treatment of adults with tardive dyskinesia
(TD).
In accordance with General Instruction B.2 of Form8-K,the
information in this Current Report on Form8-K,including
Exhibit99.1, shall not be deemed filed for purposes of Section18
of the Securities Exchange Act of 1934, as amended (the Exchange
Act) or otherwise subject to the liability of that section, nor
shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act,
except as expressly set forth by specific reference in such a
filing.
Item9.01 Financial Statements and Exhibits.
| (d) | The following exhibit is filed with this report. |
|
ExhibitNo. |
Description of Exhibit |
|
| 99.1 | Press Release, dated April 11, 2017 |
About NEUROCRINE BIOSCIENCES, INC. (NASDAQ:NBIX)
Neurocrine Biosciences, Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine-based diseases and disorders. The Company’s two lead late-stage clinical programs are Elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc. (AbbVie), and NBI-98854 (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. The Company focuses on developing NBI-640756 against Essential tremor. Its research and development focuses on addressing diseases and disorders of the central nervous and endocrine systems, which include therapeutic categories ranging from hypothalamic-pituitary-adrenal (HPA) disorders to stress-related disorders and neurological/neuropsychiatric diseases. Its Corticotropin-Releasing Factor (CRF) is a hypothalamic hormone released directly into the hypophyseal portal vasculature. NEUROCRINE BIOSCIENCES, INC. (NASDAQ:NBIX) Recent Trading Information
NEUROCRINE BIOSCIENCES, INC. (NASDAQ:NBIX) closed its last trading session up +10.32 at 51.80 with 2,477,495 shares trading hands.
